Cargando…

Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations

BACKGROUND: Multiple daily subcutaneous injections (MDSIs) are mainly used for formulating an insulin therapy for diabetic patients; however, they also cause insulin-derived amyloidosis (IDA) and lead to poor glycemic control. In addition, for the continuous subcutaneous insulin infusion system (CSI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohno, Yui, Seki, Tomohiro, Kojima, Yu, Miki, Ryotaro, Egawa, Yuya, Hosoya, Osamu, Kasono, Keizo, Seki, Toshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820959/
https://www.ncbi.nlm.nih.gov/pubmed/31687164
http://dx.doi.org/10.1186/s40780-019-0151-5
_version_ 1783464054182903808
author Ohno, Yui
Seki, Tomohiro
Kojima, Yu
Miki, Ryotaro
Egawa, Yuya
Hosoya, Osamu
Kasono, Keizo
Seki, Toshinobu
author_facet Ohno, Yui
Seki, Tomohiro
Kojima, Yu
Miki, Ryotaro
Egawa, Yuya
Hosoya, Osamu
Kasono, Keizo
Seki, Toshinobu
author_sort Ohno, Yui
collection PubMed
description BACKGROUND: Multiple daily subcutaneous injections (MDSIs) are mainly used for formulating an insulin therapy for diabetic patients; however, they also cause insulin-derived amyloidosis (IDA) and lead to poor glycemic control. In addition, for the continuous subcutaneous insulin infusion system (CSII), precipitation frequently causes catheter occlusion and, if the precipitate in the formulations is amyloid, the injection of the insoluble amyloid into the subcutaneous tissue leads to IDA. The aim of this study was to conduct in vitro experiments and present a situation where insulin formulations cause precipitation and amyloid formation. METHODS: Humulin®R and NovoRapid® were used as model formulations for MDSIs and CSII, respectively. The generation of the precipitation was evaluated by measuring turbidity, and amyloid formation was evaluated by using Thioflavin T. Humulin®R was mixed with saline buffer solutions and glucose solutions to evaluate the effect of dilution. In addition, we created an experimental system to consider the effect of the time course of condition changes, and investigated the effects of insulin concentration, m-cresol existence, and pH change on the generation of the precipitate and amyloid in the formulation. RESULTS: In both the original and diluted formulations, physical stimulation resulted in the formation of a precipitate, which in most cases was an amyloid. The amyloid was likely to be formed at a near neutral pH. On the contrary, although a precipitate formed when the pH was decreased to near the isoelectric point, this precipitate was not an amyloid. Further decreases in pH resulted in the formation of amyloids, suggesting that both the positive and negative charged states of insulin tended to form amyloids. The formulation additive m-cresol suppressed amyloid formation. When additives were removed from the formulation, the amyloid-containing gel was formed in the field of substance exchange. CONCLUSIONS: To consider changes in conditions that may occur for insulin formulations, the relationship between the formation of precipitates and amyloids was demonstrated in vitro by using insulin formulations. From the in vitro study, m-cresol was shown to have an inhibitory effect on amyloid formation.
format Online
Article
Text
id pubmed-6820959
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68209592019-11-04 Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations Ohno, Yui Seki, Tomohiro Kojima, Yu Miki, Ryotaro Egawa, Yuya Hosoya, Osamu Kasono, Keizo Seki, Toshinobu J Pharm Health Care Sci Research Article BACKGROUND: Multiple daily subcutaneous injections (MDSIs) are mainly used for formulating an insulin therapy for diabetic patients; however, they also cause insulin-derived amyloidosis (IDA) and lead to poor glycemic control. In addition, for the continuous subcutaneous insulin infusion system (CSII), precipitation frequently causes catheter occlusion and, if the precipitate in the formulations is amyloid, the injection of the insoluble amyloid into the subcutaneous tissue leads to IDA. The aim of this study was to conduct in vitro experiments and present a situation where insulin formulations cause precipitation and amyloid formation. METHODS: Humulin®R and NovoRapid® were used as model formulations for MDSIs and CSII, respectively. The generation of the precipitation was evaluated by measuring turbidity, and amyloid formation was evaluated by using Thioflavin T. Humulin®R was mixed with saline buffer solutions and glucose solutions to evaluate the effect of dilution. In addition, we created an experimental system to consider the effect of the time course of condition changes, and investigated the effects of insulin concentration, m-cresol existence, and pH change on the generation of the precipitate and amyloid in the formulation. RESULTS: In both the original and diluted formulations, physical stimulation resulted in the formation of a precipitate, which in most cases was an amyloid. The amyloid was likely to be formed at a near neutral pH. On the contrary, although a precipitate formed when the pH was decreased to near the isoelectric point, this precipitate was not an amyloid. Further decreases in pH resulted in the formation of amyloids, suggesting that both the positive and negative charged states of insulin tended to form amyloids. The formulation additive m-cresol suppressed amyloid formation. When additives were removed from the formulation, the amyloid-containing gel was formed in the field of substance exchange. CONCLUSIONS: To consider changes in conditions that may occur for insulin formulations, the relationship between the formation of precipitates and amyloids was demonstrated in vitro by using insulin formulations. From the in vitro study, m-cresol was shown to have an inhibitory effect on amyloid formation. BioMed Central 2019-10-30 /pmc/articles/PMC6820959/ /pubmed/31687164 http://dx.doi.org/10.1186/s40780-019-0151-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ohno, Yui
Seki, Tomohiro
Kojima, Yu
Miki, Ryotaro
Egawa, Yuya
Hosoya, Osamu
Kasono, Keizo
Seki, Toshinobu
Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
title Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
title_full Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
title_fullStr Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
title_full_unstemmed Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
title_short Investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
title_sort investigation of factors that cause insulin precipitation and/or amyloid formation in insulin formulations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820959/
https://www.ncbi.nlm.nih.gov/pubmed/31687164
http://dx.doi.org/10.1186/s40780-019-0151-5
work_keys_str_mv AT ohnoyui investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT sekitomohiro investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT kojimayu investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT mikiryotaro investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT egawayuya investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT hosoyaosamu investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT kasonokeizo investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations
AT sekitoshinobu investigationoffactorsthatcauseinsulinprecipitationandoramyloidformationininsulinformulations